164 related articles for article (PubMed ID: 15530698)
1. Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene.
Hansen H; Okeke MI; Nilssen O; Traavik T
Vaccine; 2004 Dec; 23(4):499-506. PubMed ID: 15530698
[TBL] [Abstract][Full Text] [Related]
2. In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.
Okeke MI; Nilssen Ø; Moens U; Tryland M; Traavik T
Virol J; 2009 May; 6():55. PubMed ID: 19435511
[TBL] [Abstract][Full Text] [Related]
3. Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.
Diaz-Cánova D; Moens U; Brinkmann A; Nitsche A; Okeke MI
Front Immunol; 2024; 15():1277447. PubMed ID: 38633245
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic properties resulting from directed gene segment reassortment between wild-type A/Sydney/5/97 influenza virus and the live attenuated vaccine strain.
Parks CL; Latham T; Cahill A; O'neill RE; Passarotti CJ; Buonagurio DA; Bechert TM; D'Arco GA; Neumann G; Destefano J; Arendt HE; Obregon J; Shutyak L; Hamm S; Sidhu MS; Zamb TJ; Udem SA
Virology; 2007 Oct; 367(2):275-87. PubMed ID: 17599381
[TBL] [Abstract][Full Text] [Related]
5. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
[TBL] [Abstract][Full Text] [Related]
6. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
Wyatt LS; Carroll MW; Czerny CP; Merchlinsky M; Sisler JR; Moss B
Virology; 1998 Nov; 251(2):334-42. PubMed ID: 9837798
[TBL] [Abstract][Full Text] [Related]
7. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
[TBL] [Abstract][Full Text] [Related]
8. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
[TBL] [Abstract][Full Text] [Related]
9. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.
Di Lullo G; Soprana E; Panigada M; Palini A; Agresti A; Comunian C; Milani A; Capua I; Erfle V; Siccardi AG
J Virol Methods; 2010 Feb; 163(2):195-204. PubMed ID: 19778556
[TBL] [Abstract][Full Text] [Related]
10. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.
Carroll MW; Moss B
Virology; 1997 Nov; 238(2):198-211. PubMed ID: 9400593
[TBL] [Abstract][Full Text] [Related]
11. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells.
Nemecková S; Hainz P; Otáhal P; Gabriel P; Sroller V; Kutinová L
Acta Virol; 2001; 45(4):243-7. PubMed ID: 11885931
[TBL] [Abstract][Full Text] [Related]
12. Poxviruses as vaccine vectors.
Pastoret PP; Vanderplasschen A
Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
14. Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.
Cottingham MG; Gilbert SC
J Virol Methods; 2010 Sep; 168(1-2):233-6. PubMed ID: 20417665
[TBL] [Abstract][Full Text] [Related]
15. Measurement of Aujeszky's disease virus recombination in vitro under conditions of low multiplicity of infection.
Dangler CA; Deaver RE; Kolodziej CM
Acta Vet Hung; 1994; 42(2-3):205-8. PubMed ID: 7810413
[TBL] [Abstract][Full Text] [Related]
16. Easy and efficient protocols for working with recombinant vaccinia virus MVA.
Kremer M; Volz A; Kreijtz JH; Fux R; Lehmann MH; Sutter G
Methods Mol Biol; 2012; 890():59-92. PubMed ID: 22688761
[TBL] [Abstract][Full Text] [Related]
17. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.
Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG
J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289
[TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.
Veits J; Römer-Oberdörfer A; Helferich D; Durban M; Suezer Y; Sutter G; Mettenleiter TC
Vaccine; 2008 Mar; 26(13):1688-96. PubMed ID: 18291561
[TBL] [Abstract][Full Text] [Related]
19. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
20. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.
Suter M; Meisinger-Henschel C; Tzatzaris M; Hülsemann V; Lukassen S; Wulff NH; Hausmann J; Howley P; Chaplin P
Vaccine; 2009 Dec; 27(52):7442-50. PubMed ID: 19539582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
